semaglutide and neuropathy Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord Semaglutide may increase risk for

You may not be a good fit for GLP-1 drugs if you: Have a history of pancreatitis Live with severe gastrointestinal disorders Have a personal or family history of medullary thyroid cancer or MEN 2 Are pregnant or breastfeeding Mild side effects such as nausea, digestive discomfort, or fatigue are common, especially when starting treatment

Digestive symptoms Some people experience temporary digestive changes as their system readjusts to normal gastric emptying speeds after stopping semaglutide

Fortunately, this is manageable

The FDA conducted a thorough drug evaluation of semaglutide before approving its use for the treatment of type 2 diabetes and chronic weight management

Lower concentrations like 1 mg/mL allow for easier measurement of small doses but require larger injection volumes

When researchers observed that patients taking these drugs also experienced significant weight loss, pharmaceutical companies began developing higher-dose formulations specifically for weight management